S-(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyl ethanethioate | 1151511-28-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 硫代羧酸及其衍生物
• 英文名称: S-(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyl ethanethioate
• 英文别名: (all-Z)-5,8,11,14,17-eicosapentaen-1-yl thioacetate；S-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyl] ethanethioate
• CAS: 1151511-28-2
• 化学式: C₂₂H₃₄OS
• 分子量: 346.577
• InChiKey: OGBRSISUPURATA-JEBPEJKESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  24
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  42.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  S-(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyl ethanethioate 在 sodium hydride 、 potassium carbonate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 2.58h， 生成 ethyl 2-((5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenylthio)butanoate
  参考文献：
  名称：

  [EN] USE OF STRUCTURALLY ENHANCED FATTY ACIDS CONTAINING SULPHUR FOR PREVENTING AND/OR TREATING NON-ALCOHOLIC STEATOHEPATITIS
  [FR] UTILISATION D'ACIDES GRAS STRUCTURELLEMENT AMÉLIORÉS CONTENANT DU SOUFRE POUR PRÉVENIR ET/OU TRAITER LA STÉATOSE HÉPATIQUE NON ALCOOLIQUE

  摘要：

  本公开涉及一种预防和/或治疗需要的受试者中的非酒精性脂肪性肝炎的方法，包括向受试者投予化合物的药效量，该化合物的化学式为（II）：其中R1、R2、R3、X和Y如规范中定义；或者该盐的药用可接受的溶剂、溶剂或该盐的溶剂的药用可接受的盐。更具体地，本公开涉及一种预防和/或治疗非酒精性脂肪性肝炎的方法，包括向受试者投予化合物的药效量，该化合物的化学式为（I）：其中R2、R3和X如规范中定义；或者该盐的药用可接受的溶剂、溶剂或该盐的溶剂的药用可接受的盐。此外，本发明涉及一种化合物的化学式（I），用于预防和/或治疗非酒精性脂肪性肝炎，其中R2、R3和X如规范中定义；或者该盐的药用可接受的溶剂、溶剂或该盐的溶剂的药用可接受的盐。

  公开号：

  WO2016173923A1
• 作为产物：
  描述：

  (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaen-1-ol 、 硫代乙酸 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以79%的产率得到S-(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenyl ethanethioate
  参考文献：
  名称：

  [EN] USE OF STRUCTURALLY ENHANCED FATTY ACIDS CONTAINING SULPHUR FOR PREVENTING AND/OR TREATING NON-ALCOHOLIC STEATOHEPATITIS
  [FR] UTILISATION D'ACIDES GRAS STRUCTURELLEMENT AMÉLIORÉS CONTENANT DU SOUFRE POUR PRÉVENIR ET/OU TRAITER LA STÉATOSE HÉPATIQUE NON ALCOOLIQUE

  摘要：

  本公开涉及一种预防和/或治疗需要的受试者中的非酒精性脂肪性肝炎的方法，包括向受试者投予化合物的药效量，该化合物的化学式为（II）：其中R1、R2、R3、X和Y如规范中定义；或者该盐的药用可接受的溶剂、溶剂或该盐的溶剂的药用可接受的盐。更具体地，本公开涉及一种预防和/或治疗非酒精性脂肪性肝炎的方法，包括向受试者投予化合物的药效量，该化合物的化学式为（I）：其中R2、R3和X如规范中定义；或者该盐的药用可接受的溶剂、溶剂或该盐的溶剂的药用可接受的盐。此外，本发明涉及一种化合物的化学式（I），用于预防和/或治疗非酒精性脂肪性肝炎，其中R2、R3和X如规范中定义；或者该盐的药用可接受的溶剂、溶剂或该盐的溶剂的药用可接受的盐。

  公开号：

  WO2016173923A1

文献信息

• Novel lipid compounds
  申请人：Pronova BioPharma Norge AS

  公开号：EP2147910A1

  公开（公告）日：2010-01-27

  The present invention relates to lipid compounds of the general formula (I): wherein R1 is selected from a C10-C22 alkyl, a C10-C22 alkenyl having 1-6 double bonds, and a C10-C22 alkynyl having 1-6 triple bonds;R2 and R3 are the same or different and may be selected from a group of different substituents; Y is selected from suphur, sulfoxide, and sulfone; and X represents a carboxylic acid or a derivative thereof, a carboxylic ester, a carboxylic anhydride or a carboxamide; or a pharmaceutically acceptable salt, complex or solvate thereof. The invention also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic and inflammatory disease area.

  本发明涉及通式（I）的脂质化合物： 其中R1选自C10-C22烷基，具有1-6个双键的C10-C22烯基，具有1-6个三键的C10-C22炔基； R2和R3相同或不同，可选自不同取代基的一组；Y选自硫、亚砜和砜；X代表羧酸或其衍生物，羧酸酯，羧酸酐或羧酰胺；或其药学上可接受的盐，络合物或溶剂化物。 该发明还涉及包含这种化合物的药物组合物和脂质组合物，以及用作药物或用于治疗，特别是用于治疗与心血管、代谢和炎症相关疾病领域的这种化合物。
• [EN] LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT<br/>[FR] COMPOSÉS LIPIDIQUES À UTILISER DANS DES PRODUITS COSMÉTIQUES, EN TANT QUE SUPPLÉMENTS ALIMENTAIRES OU EN TANT QUE MÉDICAMENTS
  申请人：PRONOVA BIOPHARMA NORGE AS

  公开号：WO2009061208A1

  公开（公告）日：2009-05-14

  The present invention relates to lipid compounds of the general formula (I): wherein • R1 is selected from a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, and a C10-C21 alkynyl having 1-6 triple bonds; • R2 and R3 are the same or different and are selected from hydrogen and a C1-C6 alkyl group; and X is selected from O, S, SO, SO2, Si or Se; • n = 1 or 3; and • P1 is selected from a hydrogen, a C10-C21 alkyl, a C10-C21 alkenyl having 1-6 double bonds, and a C10-C21 alkynyl having 1-6 triple bonds, optionally substituted; or P1 is represented by: wherein P2, P3 and P4 are selected from a hydrogen, an alkyl, alkenyl, alkynyl, optionally substituted; or P1 is a phosphonate or a phosphate ester, represented by or P1 is a sulphonate or a sulphate ester, represented by wherein P5 is a hydrogen or a C1-C6 alkyl; or a pharmaceutically acceptable salt, complex or solvate thereof. Also disclosed are pharmaceutical compositions and lipid compositions comprising such compounds, and such compounds for use as medicaments, in particular for the treatment of diseases related to the cardiovascular, metabolic and inflammatory disease area.

  本发明涉及通式(I)的脂质化合物：其中•R1选择自C10-C21烷基，具有1-6个双键的C10-C21烯基和具有1-6个三键的C10-C21炔基;•R2和R3相同或不同，选择自氢和C1-C6烷基; X选择自O，S，SO，SO2，Si或Se;•n = 1或3;•P1选择自氢，C10-C21烷基，具有1-6个双键的C10-C21烯基和具有1-6个三键的C10-C21炔基，可选择性取代;或者P1由以下式子表示：其中P2，P3和P4选择自氢，烷基，烯基，炔基，可选择性取代;或者P1是磷酸酯或磷酸酯，由以下式子表示：或P1是磺酸盐或硫酸酯，由以下式子表示：其中P5为氢或C1-C6烷基;或其药学上可接受的盐，复合物或溶剂。还披露了包括这种化合物的制药组合物和脂质组合物，以及这种化合物用于作为药物，特别是用于治疗与心血管，代谢和炎症疾病相关的疾病。
• LIPID COMPOUNDS FOR USE IN COSMETIC PRODUCTS, AS FOOD SUPPLEMENT OR AS A MEDICAMENT
  申请人：Holmeide Anne Kristin

  公开号：US20100280109A1

  公开（公告）日：2010-11-04

  The present disclosure relates to lipid compounds of formula (I): wherein: R 1 is chosen from a C 10 -C 21 alkyl, a C 10 -C 21 alkenyl having 1-6 double bonds, and a C 10 -C 21 alkynyl having 1-6 triple bonds; R 2 and R 3 are the same or different and are chosen from hydrogen and a C 1 -C 6 alkyl; X is chosen from O, S, SO, SO 2 , Si, and Se; n=1 or 3; and P 1 is chosen from hydrogen; a C 10 -C 21 alkyl, a C 10 -C 21 alkenyl having 1-6 double bonds, a C 10 -C 21 alkynyl having 1-6 triple bonds, optionally substituted; a group of formula (II) or formula (III), wherein P 2 , P 3 , and P 4 are chosen from hydrogen, an alkyl, an alkenyl, and an alkynyl, optionally substituted; and a group of formula (IV) or formula (V), wherein P 5 is chosen from hydrogen and a C 1 -C 6 alkyl; or a pharmaceutically acceptable salt, complex, or solvate thereof. Also disclosed are pharmaceutical compositions and lipid compositions comprising such compounds, and methods of use thereof, for example in the treatment of diseases related to cardiovascular, metabolic, and inflammatory conditions.

  本公开涉及式（I）的脂质化合物：其中：R1选择自C10-C21烷基，具有1-6个双键的C10-C21烯基和具有1-6个三键的C10-C21炔基; R2和R3相同或不同，选择自氢和C1-C6烷基; X选择自O、S、SO、SO2、Si和Se; n=1或3; P1选择自氢; C10-C21烷基，具有1-6个双键的C10-C21烯基，具有1-6个三键的C10-C21炔基，可以是取代基；式（II）或式（III）中的一组，其中P2、P3和P4选择自氢，烷基，烯基和炔基，可以是取代基；以及式（IV）或式（V）中的一组，其中P5选择自氢和C1-C6烷基；或其药学上可接受的盐，复合物或溶剂化物。还公开了包含这些化合物的制药组合物和脂质组合物，以及使用它们的方法，例如治疗与心血管，代谢和炎症状况相关的疾病。
• NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT
  申请人：Holmeide Anne Kristin

  公开号：US20110190395A1

  公开（公告）日：2011-08-04

  The present disclosure relates to lipid compounds of general formula (I) wherein R 1 is chosen from a C 10 -C 22 alkyl group, a C 10 -C 22 alkenyl group having 1-6 double bonds, and a C 10 -C 22 alkynyl group having 1-6 triple bonds; R 2 and R 3 are the same or different and may be selected from different substituents; Y is chosen from sulphur, sulfoxide, and sulfone; and X is a carboxylic acid or a derivative thereof, a carboxylic ester, a carboxylic anhydride, or a carboxamide; or a pharmaceutically acceptable salt, complex, or solvate thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and methods of using such compounds such as for treating diseases related to cardiovascular, metabolic, and/or inflammatory diseases.

  本公开涉及通式（I）的脂质化合物，其中R1选择自C10-C22烷基，具有1-6个双键的C10-C22烯基，和具有1-6个三键的C10-C22炔基；R2和R3相同或不同，可以选择不同的取代基；Y选择自硫、亚硫酸和磺酰基；X是羧酸或其衍生物、羧酸酯、羧酸酐或羧酰胺；或其药学上可接受的盐、复合物或溶剂化物。本公开还涉及包含这种化合物的制药组合物和脂质组合物，以及使用这种化合物的方法，例如用于治疗与心血管、代谢和/或炎症相关的疾病。
• Sulphur containing lipids for use as food supplement or as medicament
  申请人：Holmeide Anne Kristin

  公开号：US08759558B2

  公开（公告）日：2014-06-24

  The present invention relates to lipid compounds of the general formula (I): wherein R1 is selected from a C10-C22 alkyl, a C10-C22 alkenyl having 1-6 double bonds, and a C10-C22alkynyl having 1-6 triple bonds; R2 and R3 are the same or different and may be selected from a group of different substituents; Y is selected from sulphur, sulfoxide, and sulfone; and X represents a carboxylic acid or a derivative thereof, a carboxylic ester, a carboxylic anhydride or a carboxamide; or a pharmaceutically acceptable salt, complex or solvate thereof. The invention also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic and inflammatory disease area.

  本发明涉及通式（I）的脂质化合物：其中R1选自C10-C22烷基，具有1-6个双键的C10-C22烯基和具有1-6个三键的C10-C22炔基；R2和R3相同或不同，可以从不同的取代基组中选择；Y选自硫、亚砜和磺酰；X代表羧酸或其衍生物、羧酸酯、羧酸酐或羧酰胺；或其药学上可接受的盐、络合物或溶剂化物。本发明还涉及包含这种化合物的制药组合物和脂质组合物，以及这种化合物作为药物或用于治疗，尤其是用于治疗与心血管、代谢和炎症相关的疾病。